Daiichi Sankyo and Merck Withdraw Lung Cancer Drug Application

Key Facts

1Daiichi Sankyo and Merck announced the withdrawal of their regulatory approval application for a lung cancer drug.

Daiichi Sankyo and Merck announced the withdrawal of their regulatory approval application for a lung cancer drug. Investing.com reported that the companies voluntarily pulled the application on September 25, 2026, although specific clinical or regulatory hurdles were not detailed in the announcement.

The withdrawal of a drug application represents a negative development for the R&D pipelines and future revenue projections of both pharmaceutical companies. This decision impacts the commercialization timeline for the treatment within the competitive oncology market.